Vaccination with chimeric mTrop2 VLPs can break self-tolerance and initiate robust cellular and humoral immune responses, markedly enhancing the presence of CD4+ and CD8+ T cells, along with NK and natural killer T (NKT) cells, within tumor tissues. The gene discussed is CD8A; the disease is neoplasm.